Euglycemic Ketoacidosis Following Coadministration of an SGLT2 Inhibitor and Tirzepatide

Division

Capital

Hospital

LewisGale Hospital Montgomery

Document Type

Abstract

Publication Date

2-13-2025

Keywords

diabetes, diabetic ketoacidosis, euglycemic ketoacidosis, tirzepatide

Disciplines

Endocrinology, Diabetes, and Metabolism | Internal Medicine | Medicine and Health Sciences

Abstract

Euglycemic ketoacidosis (EKA) is a life-threatening condition characterized by ketone production leading to systemic acidosis, dehydration, and end-organ damage. It presents similarly to diabetic ketoacidosis, except that patients have normal to slightly elevated blood glucose levels. EKA is an increasingly recognized complication of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. Recently the novel dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist tirzepatide was approved for treatment of diabetes and weight loss. Here, we describe a unique case in which a patient placed on both an SGLT2 inhibitor and tirzepatide to treat type 2 diabetes was admitted to the intensive care unit (ICU) for EKA. To our knowledge, this is the first case detailing a patient developing this serious condition after starting tirzepatide for diabetes. The patient required treatment and monitoring in an ICU to make a full recovery. As tirzepatide is a relatively new medication whose side effect profile has yet to be fully characterized, clinicians should be aware of this rare yet potentially fatal complication.

Publisher or Conference

JCEM Case Reports

Link to Full Text

Share

COinS